• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Abcam plc (Amendment)

    12/8/23 4:30:10 PM ET
    $ABCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABCM alert in real time by email
    SC 13D/A 1 p23-2944sc13da.htm ABCAM PLC

     

    UNITED STATES  
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
     
    SCHEDULE 13D/A
     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    Abcam plc

    (Name of Issuer)
     

    Ordinary shares, nominal value £0.002 per share

    (Title of Class of Securities)
     

    000380204**

    (CUSIP Number)
     

    Jon L. Mosle

    HBK Investments L.P.

    2300 North Field Street, Suite 2200

    Dallas, Texas 75201

    (214) 758-6107

     
    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    December 6, 2023

    (Date of Event which Requires Filing of this Schedule)
     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(c), 13d-1(f) or 13d-1(g), check the following box. [ ]

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    (Page 1 of 9 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 000380204 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer. Each ADS represents 1 Ordinary Share.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 000380204SCHEDULE 13D/APage 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    HBK Investments L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    - 0 -

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    - 0 -

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     

    CUSIP No. 000380204SCHEDULE 13D/APage 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    HBK Services LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    - 0 -

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    - 0 -

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

     

     

     

    CUSIP No. 000380204SCHEDULE 13D/APage 4 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    HBK Management LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    - 0 -

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    - 0 -

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    HC, OO

             

     

    CUSIP No. 000380204SCHEDULE 13D/APage 5 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

    HBK Capital Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    - 0 -

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    - 0 -

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 000380204SCHEDULE 13D/APage 6 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

    HBK Master Fund L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    - 0 -

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    - 0 -

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 000380204SCHEDULE 13D/APage 7 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

    HBK Merger Strategies Master Fund L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    - 0 -

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    - 0 -

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    - 0 -

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 000380204SCHEDULE 13D/APage 8 of 9 Pages

     

     


    The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned (“Amendment No. 3”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D, as amended.
       
    Item 4. PURPOSE OF TRANSACTION
       
      Item 4 is hereby amended and supplemented as follows:
       
      On December 6, 2023, the Issuer consummated the Proposed Transaction pursuant to which each issued and outstanding Ordinary Share was automatically converted into the right to receive $24.00 per Ordinary Share in cash (the “Closing”). In connection with the Closing, each ADS representing an Ordinary Share and each Ordinary Share held by HBK Master, HBK Merger and the Managed Account was cancelled and converted into the right to receive $24.00 in cash. As a result, the Reporting Persons no longer beneficially own any Ordinary Shares of the Issuer.
       
    Item 5. INTEREST IN SECURITIES OF THE COMPANY.
       
      Items 5(a)-(c) and (e) of the Schedule 13D are hereby amended and restated as follows:
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Other than as disclosed in Item 4, no transactions in the ADSs or Ordinary Shares have been effected by the Reporting Persons since the filing of Amendment No. 2.
       
    (e) December 6, 2023.

     

     

     

    CUSIP No. 000380204SCHEDULE 13D/APage 9 of 9 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: December 8, 2023

     

      HBK INVESTMENTS L.P.
       
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory
       
      HBK Services LLC
       
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory
       
      HBK MANAGEMENT LLC
       
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory
       
      HBK CAPITAL LTD.
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory
         
      HBK MASTER FUND L.P.
      By: HBK Services LLC, its investment advisor
       
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory
       
      HBK MERGER STRATEGIES MASTER FUND L.P.
      By: HBK Services LLC, its investment advisor
       
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

    Get the next $ABCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCM

    DatePrice TargetRatingAnalyst
    6/20/2023$23.00 → $22.00Outperform → Sector Perform
    RBC Capital Mkts
    6/16/2023$25.00Neutral → Buy
    BofA Securities
    12/14/2022$15.00Hold
    Deutsche Bank
    More analyst ratings

    $ABCM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Abcam plc

      15-12G - Abcam plc (0001492074) (Filer)

      12/18/23 4:17:02 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:24:56 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:21:28 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Completes Acquisition of Abcam

      WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS

      12/6/23 7:30:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T

      12/4/23 4:01:00 PM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par

      11/17/23 7:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abcam downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously

      6/20/23 7:17:42 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam upgraded by BofA Securities with a new price target

      BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00

      6/16/23 7:25:35 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Abcam with a new price target

      Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00

      12/14/22 7:33:18 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Financials

    Live finance-specific insights

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his "Vote AGAINST" campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher") and Abcam's governance, execution and cost control.

      9/28/23 2:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

      Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). In addition to this, he will formally request the Abcam Board of Directors to convene a General Meeting ("EGM") with the purpose of replacing the Company's Board, including the current CEO, CFO and Chairman. Jonathan Milner's decision to oppose the acquisition is informed by e

      9/14/23 8:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Danaher to acquire Abcam for $24.00 per Share

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pat

      8/28/23 7:35:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      2/12/24 5:24:03 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      1/12/24 11:40:16 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Abcam plc (Amendment)

      SC 13D/A - Abcam plc (0001492074) (Subject)

      12/8/23 4:30:10 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company's loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner's plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, has today issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael S. Baldock and Sally W. Crawford as Directors of th

      6/12/23 7:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders

      Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right to restore focus for Abcam on governance, execution, and cost control to elevate it to the valuation it rightly deserves CAMBRIDGE, England, 17 May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, a

      5/17/23 9:15:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam: Appointment of Vice President of Investor Relations

      CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (NASDAQ:ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.     Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years. Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer. Before joining Perkin Elmer, Tommy spent eight

      6/27/22 2:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care